Skip to main content

Table 3 Univariable and multivariable Cox proportional hazard analysis of factors associated with progression free survival

From: High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin

 

Univariable

Multivariable

HR (95% CI)

P

HR (95% CI)

P

Age

 

0.148

  

  ≤ 65

1

   

  > 65

0.735 (0.484–1.116)

   

Sex

 

0.149

  

 Male

0.797 (0.489–1.115)

   

 Female

1

   

ECOG PS

 

0.518

  

 0

1

   

  ≥ 1

1.139 (0.767–1.692)

   

Charlson Commorbidity index

 

0.697

  

 0

1

   

  ≥ 1

1.084 (0.722–1.626)

   

Chronic hepatitis B

 

0.155

  

 No

1

   

 Yes

1.497 (0.934–2.320)

   

Chronic hepatitis C

 

0.612

  

 No

1

   

 Yes

1.297 (0.475–3.547)

   

Liver cirrhosis

 

0.157

  

 No

1

   

 Yes

1.551 (0.844–2.851)

   

Biliary drainage

 

0.184

  

 No

1

   

 Yes

0.593 (0.275–1.281)

   

Tumor size

 

0.394

  

  ≤ 7 cm

1

   

  > 7 cm

0.838 (0.558, 1.258)

   

Vascular invasion

 

0.379

  

 No

1

   

 Yes

0.830 (0.548, 1.257)

   

Hilar invasion

 

0.181

  

 No

1

   

 Yes

0.610 (0.296, 1.258)

   

Liver metastasis

 

0.472

  

 No

1

   

 Yes

1.157 (0.777–1.723)

   

Extrahepatic organ metastasis

 

0.280

  

 No

1

   

 Yes

1.246 (0.836–1.856)

   

Distant lymph node metastasis

 

0.001

 

0.001

 No

1

 

1

 

 Yes

2.135 (1.361–3.348)

 

2.085 (1.329–3.272)

 

Number of metastatic sites

    

 0

1

   

 1

2.567 (1.064–6.194)

0.036

  

  ≥ 2

3.422 (1.467–7.985)

0.004

  

Total bilirubin

 

0.336

  

  ≤ 1.5 x ULN

1

   

  > 1.5 x ULN

0.611 (0.224–1.666)

   

Alkaline phosphatase

 

0.765

  

  ≤ 1.5 x ULN

1

   

  > 1.5 x ULN

1.066 (0.703–1.616)

   

Albumin

 

0.050

  

  < 3.5 g/dL

1.725 (1.001–2.975)

   

  ≥ 3.5 g/dL

1

   

CA 19–9

 

0.818

  

  ≤ 37 U/mL

1

   

  > 37 U/mL

0.955 (0.643–1.417)

   

PLR

 

0.006

 

0.009

  ≤ 148

1

 

1

 

  > 148

1.828 (1.193–2.800)

 

1.766 (1.155–2.703)

 

NLR

 

0.030

  

  ≤ 5

1

   

  > 5

1.738 (1.056–2.859)

   

LMR

 

0.087

  

  < 3.5

1.538 (0.939–2.520)

   

  ≥ 3.5

1

   

AGR

 

0.368

  

  < 1.2

1.200 (0.807–1.786)

   

  ≥ 1.2

1

   
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group; CA 19–9 Carbohydrate antigen 19–9; PLR Platelet-to-lymphocyte ratio; NLR Neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; AGR Albumin-to-globulin ratio